EXERCISE AND PIOGLITAZONE FOR HIV METABOLIC SYNDROMES
运动和吡格列酮治疗艾滋病毒代谢综合征
基本信息
- 批准号:7377224
- 负责人:
- 金额:$ 9.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-01 至 2007-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our prior research has examined the pathogenesis and potential treatments for metabolic complications in people living with HIV. We have adopted the "lipotoxicity" hypothesis for metabolic syndrome X to explain the pathogenesis of impaired glucose tolerance (IGT) and fat redistribution in HIV: increased lipolysis and mobilization of lipids and free fatty acids from subcutaneous adipose depots leads to their excessive deposition in muscle and liver which contributes to dyslipidemia, insulin resistance, increased hepatic glucose output, and possibly visceral fat accumulation. Effective treatments have not been identified. Consensus groups recommend regular exercise and dietary modifications as primary, and pharmacologic interventions as secondary treatments for the syndromes. In this revised application, we propose to test the efficacy of aerobic and weight lifting exercise training and an oral insulin-sensitizing agen (pioglitazone) as treatments for HIV-associated IGT and fat redistribution. We propose a 4-month, 2-group randomized study to evaluate the efficacy of pioglitazone and exercise + pioglitazone in 40 men and 40 women living with HIV and IGT and fat redistribution. We will measure: insulin senstivity, glucose disposal rate, hepatic glucose production rate (4hr-insulin modified 6.6-[2H2]-glucose tolerance test with minimal modeling); whole-body and regional fat and muscle content (1H-MRI of the abdomen and thigh & DEXA), soleus muscle and liver lipid content (1H-MRS), muscle and fat PPAR mRNA and protein expression, serum lipid profiles, and serum adiponectin levels before and at the end of 4 months of treatment. We hypothesize and exercise trainig + pioglitazone will be more effective than pioglitazone alone at improving insulin sensitivity, reducing visceral fat, liver and muscle lipid content, and increasing peripheral subcutaneous fat content in HIV-infected people. We hypothesize that combined treatment will be more effective because exercise training will activate PPAR expression in muscle and pioglitazone will activate PPAR expression in fat and muscle. We anticipate that this project will provide direct evidence that supports the combined use of exercise training and pioglitazone in people living with HIV and experiencing metabolic and anthropomorphic disorders that increase cardiovascular disease risk.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员(PI)可能已经从其他NIH来源获得了主要资金,因此可以在其他清晰的条目中代表。列出的机构适用于该中心,这不一定是调查员的机构。我们先前的研究检查了艾滋病毒患者代谢并发症的发病机理和潜在治疗方法。 We have adopted the "lipotoxicity" hypothesis for metabolic syndrome X to explain the pathogenesis of impaired glucose tolerance (IGT) and fat redistribution in HIV: increased lipolysis and mobilization of lipids and free fatty acids from subcutaneous adipose depots leads to their excessive deposition in muscle and liver which contributes to dyslipidemia, insulin resistance, increased肝葡萄糖输出,可能是内脏脂肪的积累。尚未确定有效的治疗方法。共识小组建议定期运动和饮食修饰,作为主要的饮食和药理学干预措施,作为综合症的二级治疗方法。在此修订后的应用中,我们建议测试有氧运动和举重运动训练的功效,以及口服胰岛素敏感的Agen(Pioglitazone)作为HIV相关IGT和脂肪再分配的治疗方法。我们提出了一项为期4个月的2组随机研究,以评估40名男性和40名患有HIV,IGT和IGT和脂肪重新分布的男性和40名男性和40名妇女的吡格列酮和运动 +吡格列酮的功效。我们将测量:胰岛素剂量,葡萄糖处置速率,肝葡萄糖的产量(4hr-胰岛素修饰6.6- [2H2] [2H2] - 葡萄糖耐受性测试,具有最小的建模);全身和区域脂肪和肌肉含量(腹部和大腿和Dexa的1H-MRI),比目鱼肌肉和肝脂质含量(1H-MR),肌肉和脂肪PPAR mRNA和蛋白质表达,血清脂质谱,以及在治疗4个月之前和4个月之前和在4个月之前的血清脂质含量。我们假设和运动Trainig + pioglitazone将比单独的吡格列酮更有效,它可以提高胰岛素敏感性,降低内脏脂肪,肝脏和肌肉脂质含量,并增加HIV感染的人的外周皮下脂肪含量。我们假设联合治疗将更有效,因为运动训练将激活肌肉中的PPAR表达,而吡格列酮将激活脂肪和肌肉中的PPAR表达。我们预计该项目将提供直接证据,以支持艾滋病毒感染者的运动训练和吡格列酮的综合使用,并经历了增加心血管疾病风险的代谢和拟人化疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN E YARASHESKI其他文献
KEVIN E YARASHESKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN E YARASHESKI', 18)}}的其他基金
YOGA LIFESTYLE INTERVENTION REDUCES BLOOD PRESSURE IN HIV-INFECTED ADULTS
瑜伽生活方式干预可降低感染艾滋病毒的成年人的血压
- 批准号:
8361436 - 财政年份:2011
- 资助金额:
$ 9.87万 - 项目类别:
MYOCARDIAL INSULIN RESISTANCE IS NOT WORSENED BY WELL-CONTROLLED HIV INFECTION
心肌胰岛素抵抗不会因 HIV 感染得到良好控制而恶化
- 批准号:
8361470 - 财政年份:2011
- 资助金额:
$ 9.87万 - 项目类别:
ISOTOPE RATIO MASS SPECT IN HUMAN BIOLOGY AMINO ACID METABOLISM & KINETICS
人类生物学氨基酸代谢中的同位素比质谱
- 批准号:
7721443 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别:
EXERCISE AND PIOGLITAZONE FOR HIV-METABOLIC SYNDROMES
运动和吡格列酮治疗艾滋病毒代谢综合征
- 批准号:
7721457 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别:
CHARACTERIZING THE HIV MUSCLE MITOCHONDRIAL PROTEOME
HIV 肌肉线粒体蛋白质组的特征
- 批准号:
7721452 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别:
CHARACTERIZING THE AGING MUSCLE MITOCHONDRIAL PROTEOME
表征衰老肌肉线粒体蛋白质组
- 批准号:
7721481 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别:
MYOCARDIAL FUNCTION AND FFA METABOLISM IN HIV-METABOLIC SYNDROME
HIV 代谢综合征中的心肌功能和 FFA 代谢
- 批准号:
7603362 - 财政年份:2007
- 资助金额:
$ 9.87万 - 项目类别:
EXERCISE AND PIOGLITAZONE FOR HIV METABOLIC SYNDROMES
运动和吡格列酮治疗艾滋病毒代谢综合征
- 批准号:
7603337 - 财政年份:2007
- 资助金额:
$ 9.87万 - 项目类别:
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMES
瑜伽治疗艾滋病毒代谢综合征
- 批准号:
7603354 - 财政年份:2007
- 资助金额:
$ 9.87万 - 项目类别:
REDUCING PLASMA HIV RNA IMPROVES MUSCLE AMINO ACID METABOLISM
减少血浆 HIV RNA 改善肌肉氨基酸代谢
- 批准号:
7355251 - 财政年份:2006
- 资助金额:
$ 9.87万 - 项目类别:
相似国自然基金
染色质重塑蛋白ARID1B通过改变H3K4me3表达介导顺铂所致卵巢功能损伤的机制及吡格列酮对其的靶向阻遏研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
染色质重塑蛋白ARID1B通过改变H3K4me3表达介导顺铂所致卵巢功能损伤的机制及吡格列酮对其的靶向阻遏研究
- 批准号:82101702
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
SMSCs源外泌体负载吡格列酮通过PPARγ促骨关节炎软骨稳态平衡的机制研究
- 批准号:81901640
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
吡格列酮作为增效剂治疗双相障碍抑郁发作的疗效研究及机制探索
- 批准号:81601184
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
mitoNEET在细胞铁硫簇转运中的作用及调节机制研究
- 批准号:31200587
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
生长激素释放激素类似物可改善非酒精性脂肪肝及相关心血管风险
- 批准号:
10433832 - 财政年份:2018
- 资助金额:
$ 9.87万 - 项目类别:
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
生长激素释放激素类似物可改善非酒精性脂肪肝及相关心血管风险
- 批准号:
9923645 - 财政年份:2018
- 资助金额:
$ 9.87万 - 项目类别:
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
生长激素释放激素类似物可改善非酒精性脂肪肝及相关心血管风险
- 批准号:
9522472 - 财政年份:2018
- 资助金额:
$ 9.87万 - 项目类别:
EXERCISE TRAINING AUGMENTS THE PERIPHERAL INSULIN SENSITIZING EFFECTS
运动训练增强外周胰岛素增敏作用
- 批准号:
8361446 - 财政年份:2011
- 资助金额:
$ 9.87万 - 项目类别:
EXERCISE AND PIOGLITAZONE FOR HIV-METABOLIC SYNDROMES
运动和吡格列酮治疗艾滋病毒代谢综合征
- 批准号:
7721457 - 财政年份:2008
- 资助金额:
$ 9.87万 - 项目类别: